摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-propionyl-3,5-dimethylfuran | 75426-42-5

中文名称
——
中文别名
——
英文名称
2-propionyl-3,5-dimethylfuran
英文别名
1-(3,5-dimethylfuran-2-yl)propan-1-one
2-propionyl-3,5-dimethylfuran化学式
CAS
75426-42-5
化学式
C9H12O2
mdl
——
分子量
152.193
InChiKey
FKICBCSIEOCHKT-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    228.6±35.0 °C(Predicted)
  • 密度:
    0.995±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.2
  • 重原子数:
    11
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.44
  • 拓扑面积:
    30.2
  • 氢给体数:
    0
  • 氢受体数:
    2

反应信息

  • 作为反应物:
    描述:
    2-propionyl-3,5-dimethylfuran 作用下, 以 乙醇 为溶剂, 反应 15.0h, 以67%的产率得到2-ethyl-4,6-dimethyl-3-hydroxypyridine
    参考文献:
    名称:
    [EN] SUBSTITUTED 3 -HYDROXYPYRIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF
    [FR] 3-HYDROXYPYRIDINES SUBSTITUÉES ET COMPOSITIONS PHARMACEUTIQUES ASSOCIÉES
    摘要:
    本发明涉及一种新型治疗化合物,其化学式为(I),其中R1选自C2-8烷基组,R2独立地选自C1-8烷基组,R3独立地选自H和C1-8烷基组,R4独立地选自C1-8烷基或其药学上可接受的盐,含有这些化合物的药物组合物,用作药物的化合物以及用于制造特定药物的化合物的用途。本发明还涉及涉及通过给予这些化合物进行治疗的方法。这些新型化合物可用于治疗伴随胰岛素受体信号功能障碍的与年龄相关的疾病。
    公开号:
    WO2009078746A1
  • 作为产物:
    描述:
    2,4-二甲基呋喃丙酸酐磷酸 作用下, 以 为溶剂, 反应 2.0h, 以41%的产率得到2-propionyl-3,5-dimethylfuran
    参考文献:
    名称:
    [EN] SUBSTITUTED 3 -HYDROXYPYRIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF
    [FR] 3-HYDROXYPYRIDINES SUBSTITUÉES ET COMPOSITIONS PHARMACEUTIQUES ASSOCIÉES
    摘要:
    本发明涉及一种新型治疗化合物,其化学式为(I),其中R1选自C2-8烷基组,R2独立地选自C1-8烷基组,R3独立地选自H和C1-8烷基组,R4独立地选自C1-8烷基或其药学上可接受的盐,含有这些化合物的药物组合物,用作药物的化合物以及用于制造特定药物的化合物的用途。本发明还涉及涉及通过给予这些化合物进行治疗的方法。这些新型化合物可用于治疗伴随胰岛素受体信号功能障碍的与年龄相关的疾病。
    公开号:
    WO2009078746A1
点击查看最新优质反应信息

文献信息

  • SUBSTITUTED 3 -HYDROXYPYRIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF
    申请人:Biryukov Dmitri Valerievich
    公开号:US20100261764A1
    公开(公告)日:2010-10-14
    The present invention relates to novel therapeutic compounds of formula (I) wherein R 1 is selected from the group consisting of C 2-8 alkyl, R 2 is a methyl group, R 3 is independently selected from the group consisting of H and C 1-8 alkyl, R 4 is independently selected from the group consisting of C 1-8 alkyl or pharmaceutically acceptable salts thereof, pharmaceutical compositions containing the same, the compounds for use as medicaments, and use of the compounds for the manufacture of specific medicaments. The present invention also concerns a method of treatment involving administration of the compounds. The novel compounds are useful for the treatment of age-related disorders accompanied with dysfunctional insulin receptor signaling.
    本发明涉及公式(I)的新型治疗化合物,其中R1选自C2-8烷基组,R2为甲基基团,R3独立地选自H和C1-8烷基组,R4独立地选自C1-8烷基或其药学上可接受的盐,含有该化合物的制药组合物,用作药物的化合物以及用于制造特定药物的化合物的用途。本发明还涉及涉及给予该化合物的治疗方法。这些新型化合物对于治疗伴随着胰岛素受体信号失调的与年龄相关的疾病是有用的。
  • Process for producing acylaromatic compounds
    申请人:SUMITOMO CHEMICAL COMPANY, LIMITED
    公开号:EP0339599A2
    公开(公告)日:1989-11-02
    Acylaromatic compounds Q - - R (Q: aromatic compound residue; R: straight, branched or cyclic aliphatic group, aromatic group or araliphatic group) are prepared in high yield by a reaction, in the presence of a boron trifluoride complex catalyst, of an aromatic compound with R - O -CHXY (X: H, Cl, Br; Y: Cl, Br) or with RCOOH in the presence of (XYCHCO)₂O.
    酰芳香族化合物 Q - - R (Q:芳香族化合物残基;R:直链、支链或环状脂肪族基团、芳香族基团或脂肪族基团)是在三氟化硼络合物催化剂存在下,通过芳香族化合物与以下基团反应,以高产率制备的 R-O-CHXY(X:H、Cl、Br;Y:Cl、Br)或在 (XYCHCO)₂O 存在下与 RCOOH 反应。
  • SUBSTITUTED 3 -HYDROZYPYRIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF
    申请人:BIRYUKOV Dmitri Valerievich
    公开号:US20120270908A1
    公开(公告)日:2012-10-25
    Therapeutic compounds of formula (I) wherein R1 is selected from the group consisting of C 2-8 alkyl, R2 is independently selected from the group consisting of C 1-8 alkyl, R3 is independently selected from the group consisting of H and C 1-8 alkyl, R4 is independently selected from the group consisting of C 1-8 alkyl or pharmaceutically acceptable salts thereof, pharmaceutical compositions containing the same, the compounds for use as medicaments, and use of the compounds for the manufacture of specific medicaments. Also, a method of treatment involving administration of the compounds. The compounds are useful for the treatment of age-related disorders accompanied with dysfunctional insulin receptor signaling.
  • US5235068A
    申请人:——
    公开号:US5235068A
    公开(公告)日:1993-08-10
  • [EN] SUBSTITUTED 3 -HYDROXYPYRIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF<br/>[FR] 3-HYDROXYPYRIDINES SUBSTITUÉES ET COMPOSITIONS PHARMACEUTIQUES ASSOCIÉES
    申请人:BIRYUKOV DMITRI VALERIEVICH
    公开号:WO2009078746A1
    公开(公告)日:2009-06-25
    The present invention relates to novel therapeutic compounds of formula (I) wherein R1 is selected from the group consisting of C2-8alkyl, R2 is independently selected from the group consisting of C1-8alkyl, R3 is independently selected from the group consisting of H and C1-8alkyl, R4 is independently selected from the group consisting of C1-8alkyl or pharmaceutically acceptable salts thereof, pharmaceutical compositions containing the same, the compounds for use as medicaments, and use of the compounds for the manufacture of specific medicaments. The present invention also concerns a method of treatment involving administration of the compounds. The novel compounds are useful for the treatment of age-related disorders accompanied with dysfunctional insulin receptor signaling.
    本发明涉及一种新型治疗化合物,其化学式为(I),其中R1选自C2-8烷基组,R2独立地选自C1-8烷基组,R3独立地选自H和C1-8烷基组,R4独立地选自C1-8烷基或其药学上可接受的盐,含有这些化合物的药物组合物,用作药物的化合物以及用于制造特定药物的化合物的用途。本发明还涉及涉及通过给予这些化合物进行治疗的方法。这些新型化合物可用于治疗伴随胰岛素受体信号功能障碍的与年龄相关的疾病。
查看更多